Protara Therapeutics, Inc. Payments to Acquire Marketable Securities
Protara Therapeutics, Inc. (TARA) reported Payments to Acquire Marketable Securities of $63.09 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireMarketableSecurities · last filed 2026-08-11
- Protara Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-06-30 was $19.23M, a 62.80% decline year-over-year.
- Protara Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2026-03-31 was $43.86M, a 33.36% decline year-over-year.
- Protara Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-12-31 was $62.71M.
- Protara Therapeutics, Inc. payments to acquire marketable securities for the quarter ending 2025-09-30 was $24.41M.
- Protara Therapeutics, Inc. payments to acquire marketable securities for fiscal 2025 was $204.63M, a 596.45% increase from fiscal 2024.
- Protara Therapeutics, Inc. payments to acquire marketable securities for fiscal 2024 was $29.38M, a 141.11% increase from fiscal 2023.
- Protara Therapeutics, Inc. payments to acquire marketable securities for fiscal 2023 was $12.19M, a 72.02% decline from fiscal 2022.
- Protara Therapeutics, Inc. payments to acquire marketable securities for fiscal 2022 was $43.55M.
| Period end | Payments to Acquire Marketable Securities 3 month | Payments to Acquire Marketable Securities 6 month | Payments to Acquire Marketable Securities 9 month | Payments to Acquire Marketable Securities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $19.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $63.09M 10-Q · filed 2026-08-11 | $125.80M derived: sum of 3 quarters · filed 2026-08-11 | $150.21M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $43.86M 10-Q · filed 2026-05-13 | $106.56M derived: sum of 2 quarters · filed 2026-05-13 | $130.98M derived: sum of 3 quarters · filed 2026-05-13 | $182.68M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $62.71M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $87.12M derived: sum of 2 quarters · filed 2026-03-10 | $138.82M derived: sum of 3 quarters · filed 2026-08-11 | $204.63M 10-K · filed 2026-03-10 |
| 2025-09-30 | $24.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $76.11M derived: sum of 2 quarters · filed 2026-08-11 | $141.92M 10-Q · filed 2025-11-10 | $141.92M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $51.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $117.51M 10-Q · filed 2026-08-11 | $117.51M derived: sum of 3 quarters · filed 2026-08-11 | |
| 2025-03-31 | $65.81M 10-Q · filed 2026-05-13 | $65.81M derived: sum of 2 quarters · filed 2026-05-13 | ||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $29.38M 10-K · filed 2026-03-10 | ||
| 2024-09-30 | $29.38M 10-Q · filed 2025-11-10 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | $12.19M 10-K · filed 2025-03-05 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $0.00 derived: sum of 2 quarters · filed 2024-11-12 | $12.19M 10-Q · filed 2024-11-12 | $41.31M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $12.19M 10-Q · filed 2024-08-06 | $41.31M derived: sum of 3 quarters · filed 2024-08-06 | $41.31M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $12.19M 10-Q · filed 2024-05-02 | $41.31M derived: sum of 2 quarters · filed 2024-05-02 | $41.31M derived: sum of 3 quarters · filed 2024-05-02 | |
| 2022-12-31 | $29.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $29.12M derived: sum of 2 quarters · filed 2024-03-13 | $43.55M 10-K · filed 2024-03-13 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | $14.43M 10-Q · filed 2023-11-03 | ||
| 2022-06-30 | $14.43M 10-Q · filed 2023-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |